Cost-effectiveness of biological treatment of ulcerative colitis – a systematic review

Ewa Stawowczyk; Paweł Kawalec

doi:10.5114/pg.2017.68166

eISSN: 1897-4317
ISSN: 1895-5770

Gastroenterology Review/Przegląd Gastroenterologiczny

Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Rada naukowa Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac

Panel Redakcyjny

Zgłaszanie i recenzowanie prac online

NOWOŚĆ

Portal dla gastroenterologów!

www.egastroenterologia.pl

Wyszukiwanie

Zasady redakcyjne

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Otwarty dostęp

2/2017
vol. 12

Poleć ten artykuł:

Wyślij znajomemu

Skopiuj link:

Udostępnij:

streszczenie artykułu:

Metaanaliza

Cost-effectiveness of biological treatment of ulcerative colitis – a systematic review

Ewa Stawowczyk

,

Paweł Kawalec

DOI: https://doi.org/10.5114/pg.2017.68166

Data publikacji online: 2017/06/13

Pełna treść artykułu Pobierz cytowanie

Metryki PlumX:

The aim of this systematic review was to collect and summarise all current data on the cost-effectiveness of biological treatment in ulcerative colitis. A literature search was conducted using the Medline, Embase, Centre for Reviews and Dissemination databases and included all cost-effectiveness analyses comparing biological treatment with any comparator. We identified 277 records of which 10 were included in this review. Eighty percent of identified analyses used quality-adjusted life years (QALY) as a measure of outcome. The most commonly assessed biological agent was infliximab. Half of the eight economic analyses, with QALY as an outcome, showed the cost-effectiveness of biological treatment against the comparator. Incremental cost-effectiveness ratios (ICER) ranged from 15,748 euro to 450,791 euro. The highest ICER values were observed when biologicals were compared with standard care alone. This systematic review revealed that in some cases the biological treatment, despite its clinical effectiveness, is too expensive and exceeds the national threshold value.

Cost-effectiveness of biological treatment of ulcerative colitis – a systematic review

Ewa Stawowczyk , Paweł Kawalec

Ewa Stawowczyk

,

Paweł Kawalec